Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Pharmaceuticals
    • Sun Pharma, Rockwell...

    Sun Pharma, Rockwell Medical ink licensing pact for Triferic in India

    MD bureauWritten by MD bureau Published On 2020-01-16T10:30:24+05:30  |  Updated On 16 Jan 2020 10:30 AM IST
    Sun Pharma, Rockwell Medical ink licensing pact for Triferic in India


    As per the terms of the agreement, Sun Pharma will be the exclusive development and commercialisation partner for Triferic during the term of the agreement, subject to its approval in India.

    New Delhi: Sun Pharmaceutical Industries on Wednesday said it has entered into a licensing agreement with US-based Rockwell Medical to commercialise Triferic , an iron replacement and haemoglobin maintenance drug in India.


    "Sun Pharma....today announced that one of its wholly-owned subsidiaries has entered into exclusive licensing and supply agreements with Rockwell Medical Inc (Rockwell), to commercialise Rockwell's Triferic, a proprietary iron replacement and haemoglobin maintenance drug, for treating anaemia in hemodialysis patients in India," the drug firm said in a regulatory filing.


    As per the terms of the agreement, Sun Pharma will be the exclusive development and commercialisation partner for Triferic during the term of the agreement, subject to its approval in India.


    Triferic is the only USFDA-approved therapy in the US indicated to replace iron and maintain haemoglobin in hemodialysis patients via dialysate during each dialysis treatment.

    In consideration for the license, Rockwell will be eligible for upfront and milestone payments as well as a royalty on net sales, the filing said but added that "the financial terms of the agreement are confidential".

    Read Also: Sun Pharma Arm-SPARC, Bioprojet Ink Licensing Pact For Auto-Immune Diseases Drug SCD-044



    "Triferic is an innovative anaemia therapy for patients who are undergoing haemodialysis and offers a unique treatment option. Triferic will help Sun Pharma expand its portfolio in its core therapy areas," Sun Pharma CEO of India business Kirti Ganorkar said.


    According to the 2017 Global Burden of Disease Study, chronic kidney disease was the tenth leading cause of mortality in India, having risen from 14th rank in 2007.


    The shares of Sun Pharmaceutical Industries were trading at Rs 447.50, up 0.38 per cent on BSE in morning trade.

    Read Also: Sun Pharma Plea To Refix Price Of Ciprofloxacin Hydrochloride Injection Rejected

    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    MD bureau
    MD bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok